大三甲执行药械代表备案!违规操作将停用产品

2019-03-26 联盟菌 医疗器械经销商联盟/医药代表/人民网

3月21日,浙江省肿瘤医院举办清廉医院共建专题会,会上明确药械商代表要严格按照协议约定来院开展各项正常工作,遵守医院的规章制度,正常进行产品推介、学术活动、项目洽谈,严格执行《医院关于行风建设若干规定》,必须做好药械商代表的登记备案,挂牌来院来访。

3月21日,浙江省肿瘤医院举办清廉医院共建专题会,会上明确药械商代表要严格按照协议约定来院开展各项正常工作,遵守医院的规章制度,正常进行产品推介、学术活动、项目洽谈,严格执行《医院关于行风建设若干规定》,必须做好药械商代表的登记备案,挂牌来院来访。

这是杭州市又一所要求药械商代表备案的医院。未按医院规定执行,一经查实,承担相应责任。

据“医药代表”公众号了解,该院本周已经在收取厂家代表的备案表电子版及照片,纸质盖章版要求3月底前交至医院。

除此之外,会上还明确该院原有纪检监察室的基础上,在全院范围内专门聘任33名特邀监察员,创建39个工作群,明确监管范围和对象,亮明身份,开展药械商代表阳光监督。

在医院行政楼、门诊大厅、1号楼、2号楼等区域进行张挂《关于加强行风建设的若干规定》。同时,对于违规操作的药械商代表我院进行暂停药品耗材使用的处罚,进行震慑警示;

加强医用耗材试剂的监管。调查摸底手术室耗材使用情况,针对一次性穿刺器进行为期一个月的使用登记,对于冗余品规提出停用建议,与上年度同期对比下降明显。规范采购行为,严格把关临时采购,99%以上的医用耗材通过招议标采购,同时严格按招(议)标时承诺的成本比例对检验试剂进行考核,对超出承诺比例的货款不予支付,实现成本有效管控。

早在去年9月,浙江省另一家三甲医院,浙江医院发布一则通知规定:要求所有的医药(械)代表都必须持证上岗!

浙江医院还给持证上岗的药械代表定了7项规定:

不得干扰医疗业务工作和诊疗秩序;

不得在门诊时间进出诊室开展业务工作;

不得院内进行产品推销活动;开展业务交流均应公开进行。

不得违规向科室或职工个人赠送财物或提供服务;

不得“统方”;

不得违反法律法规及其他行风纪律等规定。

湖南:三甲医院严禁药械商代表科室窜访、家中拜访

无独有偶,近日,株洲市中医伤科医院这家大三甲医院召开药品、设备、耗材供应商(经销商)集体廉政谈话会,约谈该院所有有业务往来的药品、设备、耗材供应商(经销商)。

值得注意的是,株洲市中医伤科医院还特别针对药品、设备、耗材购销领域,提出了如下“四个严禁”:

严禁以任何形式给医务人员回扣,

严禁供应商代表进入病区、门诊、药房等非业务联系科室窜访,

严禁到相关负责人及工作人员家中访谈或向介绍人提供任何好处费,

严禁统方行为,严禁以次充好,降低产品质量。

这也就是说,今后不只是医药代表,医械代表进入科室窜访、去主任家中拜访也要被严格禁止!

北京三甲医院:不止药械代表,药械企业所有人员必须登记拜访

据“医药代表”公众号消息,北京海淀医院贴出通知,根据北京市、区卫生计生部门相关要求,从去年8月11日起,医院对来访的医药生产经营企业的工作人员、代表、代理人进行统筹接待登记,登记部门为医院纪检监察办公室。

从通知来看,被要求登记的不仅仅是药械代表,还包括药械生产经营企业的所有从业人员。

而且值得注意的是,这一通知是由该院医学装备科发出的,则意味着面向的不止医药生产经营企业,还包括医疗器械企业。

并且,通知明确要求,医院工作人员不得以任何理由接待关联人员,所有要来医院拜访的药械生产经营企业工作人员,必须先去纪检监察办公室登记审查,再去医学装备科。这意味着,纪检监察办将是医院反腐前沿的一道阵线。

此前上海市就发布关于征求《上海市医药代表登记管理试行办法(征求意见稿)》,要求全上海医药代表必须进行登记备案。

上海多家医院也加大对药械商代表院内拜访的严监管,意味着这项新规已经开始加速落地!药械商代表受到前所未有的严格监管!

在一个成熟的医疗市场,原研药和手术器械在进入临床的过程中,的确需要来自厂商的学术推广和专业支持,与此同时,药品、医疗器械正常的商业推广也是药械代表的工作。但法律边界在于不得通过利益诱导医生的处方行为。

一旦这一边界被突破,带金销售必然将成为医改浪潮之下被重点打击的对象!不仅仅是药代,医械代表、销售,无疑是医药购销反腐领域的重点监管对象!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1747738, encodeId=eea71e47738cf, content=<a href='/topic/show?id=528294510d4' target=_blank style='color:#2F92EE;'>#违规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94510, encryptionId=528294510d4, topicName=违规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe7b35947177, createdName=zhao4628, createdTime=Thu Nov 14 23:36:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399424, encodeId=e0b11399424f1, content=<a href='/topic/show?id=8bbe8e611a0' target=_blank style='color:#2F92EE;'>#药械#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87611, encryptionId=8bbe8e611a0, topicName=药械)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58f2204373, createdName=fengyqf, createdTime=Thu Mar 28 05:36:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552503, encodeId=5b241552503e6, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Thu Mar 28 05:36:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590963, encodeId=a097159096395, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Thu Mar 28 05:36:00 CST 2019, time=2019-03-28, status=1, ipAttribution=)]
    2019-11-14 zhao4628
  2. [GetPortalCommentsPageByObjectIdResponse(id=1747738, encodeId=eea71e47738cf, content=<a href='/topic/show?id=528294510d4' target=_blank style='color:#2F92EE;'>#违规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94510, encryptionId=528294510d4, topicName=违规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe7b35947177, createdName=zhao4628, createdTime=Thu Nov 14 23:36:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399424, encodeId=e0b11399424f1, content=<a href='/topic/show?id=8bbe8e611a0' target=_blank style='color:#2F92EE;'>#药械#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87611, encryptionId=8bbe8e611a0, topicName=药械)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58f2204373, createdName=fengyqf, createdTime=Thu Mar 28 05:36:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552503, encodeId=5b241552503e6, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Thu Mar 28 05:36:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590963, encodeId=a097159096395, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Thu Mar 28 05:36:00 CST 2019, time=2019-03-28, status=1, ipAttribution=)]
    2019-03-28 fengyqf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1747738, encodeId=eea71e47738cf, content=<a href='/topic/show?id=528294510d4' target=_blank style='color:#2F92EE;'>#违规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94510, encryptionId=528294510d4, topicName=违规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe7b35947177, createdName=zhao4628, createdTime=Thu Nov 14 23:36:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399424, encodeId=e0b11399424f1, content=<a href='/topic/show?id=8bbe8e611a0' target=_blank style='color:#2F92EE;'>#药械#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87611, encryptionId=8bbe8e611a0, topicName=药械)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58f2204373, createdName=fengyqf, createdTime=Thu Mar 28 05:36:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552503, encodeId=5b241552503e6, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Thu Mar 28 05:36:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590963, encodeId=a097159096395, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Thu Mar 28 05:36:00 CST 2019, time=2019-03-28, status=1, ipAttribution=)]
    2019-03-28 陈吴1239
  4. [GetPortalCommentsPageByObjectIdResponse(id=1747738, encodeId=eea71e47738cf, content=<a href='/topic/show?id=528294510d4' target=_blank style='color:#2F92EE;'>#违规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94510, encryptionId=528294510d4, topicName=违规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe7b35947177, createdName=zhao4628, createdTime=Thu Nov 14 23:36:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399424, encodeId=e0b11399424f1, content=<a href='/topic/show?id=8bbe8e611a0' target=_blank style='color:#2F92EE;'>#药械#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87611, encryptionId=8bbe8e611a0, topicName=药械)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58f2204373, createdName=fengyqf, createdTime=Thu Mar 28 05:36:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552503, encodeId=5b241552503e6, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Thu Mar 28 05:36:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590963, encodeId=a097159096395, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Thu Mar 28 05:36:00 CST 2019, time=2019-03-28, status=1, ipAttribution=)]
    2019-03-28 cenghis